Actively Recruiting
STrategies for Antithrombotic tReatment Following Transcatheter Edge-to-Edge Repair in Patients Without an Indication for Oral Anticoagulant
Led by Chinese Academy of Medical Sciences, Fuwai Hospital · Updated on 2026-03-09
1032
Participants Needed
1
Research Sites
217 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Mitral regurgitation (MR) is the most common valvular heart disease, affecting approximately 24.2 million people worldwide (with a higher prevalence in older age groups). Transcatheter edge-to-edge repair (TEER) is now a well-established strategy in high-risk patients with MR. Globally, over 250,000 patients have benefited from the TEER technique. However, no dedicated study has prospectively evaluated different antithrombotic strategies following TEER in patients undergone TEER procedure. Current guidelines do not provide any recommendations for the antithrombotic management of TEER. Consequently, considerable treatment variation exists in clinical studies and practice. The investigators will conduct a multicenter, open-label randomized trial to compare different antithrombotic strategies following TEER in patients without an indication for OAC.
CONDITIONS
Official Title
STrategies for Antithrombotic tReatment Following Transcatheter Edge-to-Edge Repair in Patients Without an Indication for Oral Anticoagulant
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Successful TEER procedure, defined as technical success per MVARC criteria.
- Ability and willingness to comply with the trial protocol.
- Provision of written informed consent.
- Women of childbearing potential must use effective contraception from the time of consent until the final dose of antithrombotic therapy.
- Antithrombotic strategy approved by the investigator.
You will not qualify if you...
- Severe renal impairment (creatinine clearance < 15 mL/min or requiring dialysis).
- Ongoing postoperative bleeding (defined as overt bleeding with a ≥3.0 g/dL drop in hemoglobin or requiring ≥3 units of blood transfusion), or vascular complications following the index TEER procedure.
- Platelet count < 50 × 10^9 /L.
- Need for reoperation due to complications of the index TEER procedure.
- Recent (< 12 month) intracranial or intracerebral hemorrhage.
- Recent (< 12 month) gastrointestinal ulcers or hemorrhage.
- Hepatic disease with coagulopathy (eg, Child-Pugh class B or C cirrhosis).
- Allergy, intolerance, or contraindication to research drugs.
- Participation in another investigational drug or device study within 30 days.
- Indication for long-term oral anticoagulant.
- Absolute indication for dual antiplatelet therapy (eg, recent PCI).
- Life expectancy < 12 months.
- Pregnancy or breastfeeding.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Chinese Academy of Medical Sciences, Fuwai Hospital
Beijing, Beijing Municipality, China, 100037
Actively Recruiting
Research Team
X
Xiangbin Pan, MD,PhD
CONTACT
Z
Zizheng Liu, M.B
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here